MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MeiraGTx Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.45+0.17 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
MeiraGTx Holdings plc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License revenue | $204.64M | – | – | – | – | – | – | – | – | – | – | – | 63.7% | – |
| Service revenue - related party | $104.91M | $293.00K | $373.00K | $410.00K | $3.69M | $1.93M | $21.39M | $10.91M | $282.00K | – | – | – | 32.6% | +2742.2% |
| Service revenue | $11.89M | – | – | – | – | – | – | – | – | – | – | – | 3.7% | – |
By region
From the segment and revenue-disaggregation notes of MeiraGTx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.